About Anteis
Anteis develops biopolymer injectables and injection technologies based on biopolymer transformation. The companys products consist mainly of medical devices for Aesthetic medicine such as wrinkle fillers, body contouring, skin rehydration products; Surgical ophthalmology i.e. products for cataract and glaucoma surgery; and Orthopedics Rheumatology, for example, viscoantalgics for osteoarthritis. Anteis has 2 factories located in Switzerland, and distributes its products through an international distributors network among more than 90 countries including Europe, Brazil, Japan and USA. Anteis was acquired by Merz Pharma in 2013 from previous owners, the private equity investor Signet Healthcare Partners.
- Headquarter Meyrin, Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Anteis
Detailed funding history for Anteis
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Anteis
Anteis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Merz.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Merz is recognized as a leader in aesthetic medicine and neurotoxin therapy.
|
Locked | Locked | Locked |
Investor details for Anteis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Anteis
Investment portfolio details for Anteis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Anteis
Detailed financials for Anteis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Anteis Comparisons
Peer comparison for Anteis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Anteis
Detailed competitors of Anteis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Anteis
Complete news archive for Anteis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anteis
Anteis was founded in 2003.
Anteis is headquartered in Meyrin, Switzerland. It is registered at Meyrin, Geneva, Switzerland.
Anteis develops biopolymer injectables and injection technologies based on biopolymer transformation. The companys products consist mainly of medical devices for Aesthetic medicine such as wrinkle fillers, body contouring, skin rehydration products; Surgical ophthalmology i.e. products for cataract and glaucoma surgery; and Orthopedics Rheumatology, for example, viscoantalgics for osteoarthritis. Anteis has 2 factories located in Switzerland, and distributes its products through an international distributors network among more than 90 countries including Europe, Brazil, Japan and USA. Anteis was acquired by Merz Pharma in 2013 from previous owners, the private equity investor Signet Healthcare Partners.
Anteis has 1 investor. Key investors include Merz.